ATNT-06EVALUATION OF THE SAFETY OF GSK2256098 AND PHARMACOKINETICS OF<sup>11</sup>C-GSK2256098 IN PATIENTS WITH RECURRENT GLIOBLASTOMA BY POSITRON EMISSION TOMOGRAPHY (PET) IMAGING

Paul Mulholland(University College London Hospitals NHS Foundation Trust), Sarah P. Blagden(Churchill Hospital), Azeem Saleem, Laurie Lenox(GlaxoSmithKline (United States)), Christophe Plisson, Yan Li(Guiyang Medical University), Jianping Zhang(Fujian Medical University), Matthew Williams(Hammersmith Hospital), David Cox(GlaxoSmithKline (United Kingdom)), L H G Swartz(Research Triangle Park Foundation), Jerry M. Tolson(Research Triangle Park Foundation), Kurt R. Auger(Research Triangle Park Foundation), Ronald A. Fleming(Research Triangle Park Foundation), Graham Searle, Rajendra Singh(GlaxoSmithKline (United States)), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute)
Neuro-Oncology
November 1, 2015
10.1093/neuonc/nov205.06
Cited by 3

Related Papers

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222
Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq
|Journal of Virology|2013|210